JP2025500321A5 - - Google Patents
Info
- Publication number
- JP2025500321A5 JP2025500321A5 JP2024537118A JP2024537118A JP2025500321A5 JP 2025500321 A5 JP2025500321 A5 JP 2025500321A5 JP 2024537118 A JP2024537118 A JP 2024537118A JP 2024537118 A JP2024537118 A JP 2024537118A JP 2025500321 A5 JP2025500321 A5 JP 2025500321A5
- Authority
- JP
- Japan
- Prior art keywords
- independently selected
- optionally substituted
- compound according
- occurrence
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163293730P | 2021-12-24 | 2021-12-24 | |
| US63/293,730 | 2021-12-24 | ||
| US202263299817P | 2022-01-14 | 2022-01-14 | |
| US63/299,817 | 2022-01-14 | ||
| US202263338994P | 2022-05-06 | 2022-05-06 | |
| US63/338,994 | 2022-05-06 | ||
| PCT/US2022/053910 WO2023122320A1 (en) | 2021-12-24 | 2022-12-23 | Polypodal serotonergic compounds and prodrugs of serotonin receptor agonists and antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025500321A JP2025500321A (ja) | 2025-01-09 |
| JP2025500321A5 true JP2025500321A5 (cg-RX-API-DMAC7.html) | 2026-01-06 |
Family
ID=86903690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024537118A Pending JP2025500321A (ja) | 2021-12-24 | 2022-12-23 | 多脚型セロトニン作動性化合物ならびにセロトニン受容体アゴニスト及びアンタゴニストのプロドラッグ |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP4452939A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025500321A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023122320A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| WO2024026573A1 (en) * | 2022-08-05 | 2024-02-08 | Mindset Pharma Inc. | 3-ethylamino-indole dimers as serotonergic agents useful for the treatment of disorders related thereto |
| US20240158350A1 (en) * | 2022-10-14 | 2024-05-16 | Invyxis, Inc. | Ester analogs of psilocin, processes for the preparation thereof, and methods of use |
| WO2025045773A1 (en) * | 2023-08-25 | 2025-03-06 | Compass Pathfinder Limited | 3-(2-(dimethylamino)ethyl)-1h-indol-4-yl oligomeric derivatives |
| WO2025122513A1 (en) * | 2023-12-04 | 2025-06-12 | Delix Therapeutics, Inc. | Methods of treating neuropsychiatric disorders with non-hallucinogenic tryptamines |
| US20260021070A1 (en) * | 2024-07-19 | 2026-01-22 | Compass Pathfinder Limited | Subcutaneous formulations comprising psilocybin derivatives |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2731223A1 (fr) * | 1995-03-02 | 1996-09-06 | Pf Medicament | Nouveaux derives bi-tryptaminiques, leur procede de preparation et leur utilisation a titre de medicaments |
| US9073851B2 (en) * | 2011-10-28 | 2015-07-07 | Board Of Regents, The University Of Texas System | Compositions and methods for treating cancer |
| CA2913108A1 (en) * | 2013-05-24 | 2014-11-27 | Nestec S.A. | Pathway specific assays for predicting irritable bowel syndrome diagnosis |
| JP7273731B2 (ja) * | 2017-02-09 | 2023-05-15 | カームテック、エルエルシー | シロシビン誘導体を含む組成物及び方法 |
| AU2021215709A1 (en) * | 2020-02-04 | 2022-09-01 | Mindset Pharma Inc. | 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders |
| AU2021328726A1 (en) * | 2020-08-21 | 2023-03-02 | Compass Pathfinder Limited | Novel psilocin derivatives having prodrug properties |
| AU2023235712A1 (en) * | 2022-03-18 | 2024-11-07 | Enveric Biosciences Canada Inc. | C4-substituted tryptamine derivatives and methods of using |
| JP2025525952A (ja) * | 2022-08-05 | 2025-08-07 | マインドセット ファーマ インコーポレイテッド | セロトニンに関する障害の治療に有用であるセロトニン作動薬としての３－ピロリジン－インドール二量体 |
| WO2024026573A1 (en) * | 2022-08-05 | 2024-02-08 | Mindset Pharma Inc. | 3-ethylamino-indole dimers as serotonergic agents useful for the treatment of disorders related thereto |
| US20240158350A1 (en) * | 2022-10-14 | 2024-05-16 | Invyxis, Inc. | Ester analogs of psilocin, processes for the preparation thereof, and methods of use |
-
2022
- 2022-12-23 EP EP22912515.8A patent/EP4452939A4/en active Pending
- 2022-12-23 WO PCT/US2022/053910 patent/WO2023122320A1/en not_active Ceased
- 2022-12-23 JP JP2024537118A patent/JP2025500321A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024531229A5 (cg-RX-API-DMAC7.html) | ||
| DK153940C (da) | Analogifremgangsmaade til fremstilling af 1-aryloxy-3-alkylamino-2-propanol-derivater eller farmaceutisk anvendelige, ugiftige syreadditionssalte deraf | |
| JP2016121196A5 (cg-RX-API-DMAC7.html) | ||
| Bentrude et al. | Conformations of saturated cyclic phosphorus heterocycles. II. 5-tert-Butyl-2-amino-1, 3, 2-dioxaphosphorinanes. Apparent effects of phosphorus-nitrogen vicinal interactions on the conformational energy of amino groups on trivalent phosphorus and the influence of lone pair orientation on 3FHeqP | |
| JP2010528089A5 (cg-RX-API-DMAC7.html) | ||
| JP2018519302A5 (cg-RX-API-DMAC7.html) | ||
| JP2011016800A5 (cg-RX-API-DMAC7.html) | ||
| JP2023553835A5 (cg-RX-API-DMAC7.html) | ||
| NO20063452L (no) | Benzamid-derivater og deres anvendelse som glukokinaseaktiversingsmidler | |
| JP2015532275A5 (cg-RX-API-DMAC7.html) | ||
| NO20070032L (no) | Hetroarylbenzamid-derivater for anvendelse som GLK-aktivatorer ved behandling av diabetes | |
| JP2018529745A5 (cg-RX-API-DMAC7.html) | ||
| CY1114932T1 (el) | Αντιπαρασιτικοι παραγοντες | |
| RU2009133453A (ru) | Фторсодержащее пиразолкарбонитрильное производное и способ его получения и фторсодержащее производное пиразолкарбоновой кислоты, полученное с применением фторсодержащего пиразолкарбонитрильного производного и способ его получения | |
| JP2023533203A5 (cg-RX-API-DMAC7.html) | ||
| JP2023518776A5 (cg-RX-API-DMAC7.html) | ||
| IL318795A (en) | 3-Ethylaminoindole dimers as serotonergic agents useful for the treatment of related disorders | |
| JP2022529309A5 (cg-RX-API-DMAC7.html) | ||
| Ryabov et al. | Structural and mechanistic look at the orthoplatination of aryl oximes by dichlorobis (sulfoxide or sulfide) platinum (II) complexes | |
| JP2018090537A5 (cg-RX-API-DMAC7.html) | ||
| Erb et al. | Synthesis of Ferrocenesulfonyl Chloride: Key Intermediate toward Ferrocenesulfonamides | |
| Zaguzin et al. | Strong halogen bonds with guest molecules in a Co (ii) 2, 5-diiodoterephthalate metal–organic framework | |
| IL318794A (en) | 3-Pyrrolidine Indole Dimers as Serotonergic Agents Useful for the Treatment of Related Disorders | |
| Bříza et al. | 2-(Perfluoroalkyl) ethyl triflates, building blocks for the synthesis of bis (polyfluoroalkylated) cyclopentadienes | |
| CN118324710B (zh) | 一种噁二唑化合物的制备方法 |